Posts tagged share price
Mackie ups Profound Medical price target to $4.40

Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.

Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.

Read More
JMP resumes coverage of AtriCure

MP Securities resumed coverage of AtriCure (NASDAQ:ATRC) with a “market outperform” rating and $25 price target. The stock closed at $14.39 on Wednesday.

“AtriCure is well positioned, in our view, to further develop and penetrate several large opportunities that are currently underserved in and around atrial fibrillation (AF),” writes analyst John Gillings.

Read More